Who
John F. Milligan
Director
Company insider
Files Form 4 as: Director, 4D Molecular Therapeutics; Director, Pacific Biosciences of California; Director, Kailera Therapeutics; President and CEO, Gilead Sciences.
In numbers
- Trades disclosed
- 421
- Buys
- 1
- Sells
- 46
- Bought
- $2.3M
- Sold
- $382.7M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 25 Jan 2006
- Last trade
- 17 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 18 Jun 2026 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | PACB Pacific Biosciences of Californiaoption or derivative · Life-science tools | SEC FORM 4 Code A | —223,492 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | PACB Pacific Biosciences of Californiaoption or derivative · Life-science tools | SEC FORM 4 Code A | —223,492 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,300 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | KLRA Kailera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,300 at $0.00 | filing |
| 17 Jun 2025filed 20 Jun 2025 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,750 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | PACB Pacific Biosciences of Californiaoption or derivative · Life-science tools | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | PACB Pacific Biosciences of Californiaoption or derivative · Life-science tools | SEC FORM 4 Code A | —32,179 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | PACB Pacific Biosciences of CaliforniaLife-science tools | SEC FORM 4 Code A | —22,821 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,791 at $0.00 | filing |
| 24 May 2023filed 26 May 2023 | PACB Pacific Biosciences of Californiaoption or derivative · Life-science tools | SEC FORM 4 Code A | —25,775 at $0.00 | filing |
| 23 May 2023filed 25 May 2023 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,750 at $0.00 | filing |
| 25 May 2022filed 27 May 2022 | PACB Pacific Biosciences of Californiaoption or derivative · Life-science tools | SEC FORM 4 Code A | —63,015 at $0.00 | filing |
| 23 May 2022filed 25 May 2022 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,750 at $0.00 | filing |
| 16 Jun 2021filed 21 Jun 2021 | PACB Pacific Biosciences of Californiaoption or derivative · Life-science tools | SEC FORM 4 Code A | —12,885 at $0.00 | filing |
| 17 May 2021filed 19 May 2021 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 17 May 2021filed 19 May 2021 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,250 at $0.00 | filing |
| 15 Dec 2020filed 17 Dec 2020 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Bought | $2.3M100,000 at $23.00 | filing |
| 15 Oct 2020filed 19 Oct 2020 | PACB Pacific Biosciences of Californiaoption or derivative · Life-science tools | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
News
Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?GILD · insidermonkey.com · 22 Oct 2026Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?GILD · fool.com · 18 Oct 2026Gilead Sciences Clears Its February High at $153.54GILD · 247wallst.com · 15 Oct 2026Contrasting 4D Molecular Therapeutics (NASDAQ:FDMT) and Sangamo Therapeutics (NASDAQ:SGMO)FDMT · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name John F. Milligan; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.